HONG KONG SAR - Media OutReach Newswire - 12 September 2025 - Zentrogene Laboratory, an international genetic testing institution based in Hong Kong (under Sanai Health Industry Group 01889.HK), announced the launch of its 'Y Precision' testing technology based on Next-Generation Sequencing (NGS). This locally developed innovation in Hong Kong addresses longstanding industry challenges in gender determination for twin pregnancies. It overcomes the limitations of traditional qPCR platforms, achieving the first-ever precise identification of male-female twins while significantly enhancing the accuracy of fetal cell-free DNA (cfDNA) analysis.
Traditional methods could only qualitatively detect the presence of the Y chromosome, failing to distinguish between male-male twins and male-female twins. They also lacked the capability to identify residual male cfDNA after fetal reduction procedures. Zentrogene's NGS-based technology achieves three breakthroughs:
- Fetal Signal Assessment: Utilizes whole-genome SNP scanning to confirm fetal signal presence, precisely quantify fetal fraction, and determine the number of fetal signals.
- Contamination Identification: Differentiates between false signals (e.g., contamination-derived Y chromosome fragments) and true fetal signals.
- Twin Pregnancy Precision Analysis: Independently analyzes X and Y chromosome fragments to accurately distinguish male-female twins from male-male twins.
For details, visit:
https://www.zentrogene.com/
https://www.zentrogene.com.hk/
Official Cooperation Contacts:
Telephone: +86 18051865085 (WeChat same number)
Telegram: +855 99990026
Facebook: Zentrogene
Hashtag: #Zentrogene
發佈者對本公告的內容承擔全部責任
source: Zentrogene
